Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fedorchenko Sv
Observed names:
S V Fedorchenko,
S. V. Fedorchenko,
Sergii V. Fedorchenko
Institution:
L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Sciences of Ukraine
Observed institution:
L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Sciences of Ukraine
ORCID:
0000-0002-5338-7072
Observed ORCID:
0000-0002-5338-7072
OpenAlex ID:
A5041852763
[Spontaneous HCV clearance: an association with gender, age, viral genotypes, infection transmission routes, and markers of HBV and HIV].
2010
·
S V Fedorchenko
, T L Martynovich
, et al.
·
PubMed
·
10
Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct‐acting antiviral therapy including first‐ and second‐generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin
2020
·
Sergii V. Fedorchenko
, Tatiana Martynovych
, et al.
·
Journal of Viral Hepatitis
·
6
IL-28B genetic variation, gender, age, jaundice, hepatitis C virus genotype, and hepatitis B virus and HIV co-infection in spontaneous clearance of hepatitis C virus
2019
·
Sergii V. Fedorchenko
, Anna Klimenko
, et al.
·
The Turkish Journal of Gastroenterology
·
3
PDF
Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks
2025
·
Sergii V. Fedorchenko
, Zhanna Klimenko
, et al.
·
Journal of Virology
·
2
Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing NS5A inhibitors with sofosbuvir/velpatasvir plus ribavirin for 24 weeks
2023
·
Sergii V. Fedorchenko
, Tatiana Martynovych
, et al.
·
Journal of Clinical Virology Plus
·
2
[Antiphospholipid syndrome at the onset of clinical manifestations of chronic autoimmune hepatitis of type I].
2009
·
S V Fedorchenko
, Zh B Klimenko
, et al.
·
PubMed
·
2
[Latent HBV infection in single blood donors].
2008
·
S V Fedorchenko
, L I Zanevskaia
, et al.
·
PubMed
·
2
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors
2021
·
Sergii V. Fedorchenko
, Tatiana Martynovych
, et al.
·
Journal of Medical Virology
·
1
Effectiveness of Retreatment with ombitasvir/paritaprevir/ ritonavir, dasabuvir+sofosbuvir+ribavirin in Patients with Chronic Hepatitis C, Subtype 1b and Cirrhosis, Who Failed Previous with First- and Second-generation NS5A Inhibitors
2021
·
Sergii V. Fedorchenko
, Tatiana Martynovych
, et al.
·
Archives of Clinical Microbiology
·
1
[Combined therapy with recombinant alfa-2 and gamma interferons in patients with chronic hepatitis delta virus infection].
1996
·
S V Fedorchenko
·
PubMed
·
1
[IgM anti-HBc in the differential diagnosis of co- and HDV superinfection].
1991
·
S V Fedorchenko
, S V Vozianova
·
PubMed
·
1
[Delta hepatitis as a mixed infection].
1990
·
S V Fedorchenko
, A D Vovk
, et al.
·
PubMed
·
1
Хронічні вірусні гепатити у військовослужбовців під час АТО/ООС
2024
·
V. I. Trykhlib
, S. V. Fedorchenko
, et al.
·
Ukrainian Journal of Military Medicine
Репликативная активность и генетическая гетерогенность HCV у пациентов с коинфекцией HCV/HIV и больных хроническим гепатитом С
2014
·
Sergii V. Fedorchenko
, С. Н. Антоняк
, et al.
·
Electronic archive of the library (Vitebsk State Medical University)
[Retherapy with lamivudine in hbeag-negative chronic hepatitis B patients unresponsive to interferon/peginterferon treatment].
2011
·
S V Fedorchenko
, T L Martynovich
, et al.
·
PubMed
[Combined antiviral treatment of a patient with chronic mixed hepatitis (HBV + HCV)].
2006
·
S V Fedorchenko
, T L Martynovich
·
PubMed
[The use of recombinant alfa-2 interferon in treating patients with acute and chronic viral hepatitis B].
1998
·
A D Vovk
, N V Tat'ianko
, et al.
·
PubMed
[The successful use of recombinant alfa-2 interferon in HBV-associated glomerulonephritis in a child].
1996
·
S V Fedorchenko
, D D Ivanov
·
PubMed
[The effect of recombinant alfa-2 interferon (reaferon) on the functional activity of natural killers in acute viral hepatitis B].
1995
·
I A Petrovskaia
, L Ia Kushko
, et al.
·
PubMed
[Can chronic hepatitis B patients overcome resistance to antiviral therapy due to production of antibodies to recombinant alpha-2-interferon?].
1994
·
S V Fedorchenko
·
PubMed
[The combined treatment with prednisolone and recombinant alpha 2-interferon of patients with chronic hepatitis B: the factors influencing the immune response].
1994
·
S V Fedorchenko
, A D Vovk
, et al.
·
PubMed
[Characteristics of clinical-serological diagnosis of fulminant hepatitis].
1993
·
S V Fedorchenko
·
PubMed
[The etiology of chronic anti-HBc-positive hepatitis].
1992
·
S V Fedorchenko
·
PubMed
[Diagnostic and prognostic significance of anti-HBCAG IgM in hepatitis B and its outcomes].
1991
·
S V Fedorchenko
·
PubMed
[Class-M antibodies to the nuclear antigen in chronic hepatitis B: their significance for the late prognosis].
1991
·
S V Fedorchenko
·
PubMed
Show more works
View as search
Works count:
33
Citation count:
32
H-index:
3
I10-index:
1
Year
Topic
Type